Queen Sirikit National Institute of Child Health
Ratchathewi, Bangkok, 10400, Thailand
Location status: Recruiting
NCT Number: NCT04302116
Infantile spasms (IS) are seizures associated with a severe infantile epileptic encephalopathy. Both cessation of spasms and electrographic response are necessary for the best neurodevelopmental outcomes. Adrenocorticotrophic hormone (ACTH), or prednisolone, or vigabatrin are considered the first-line treatment individually. However, ACTH expense and availability are the barriers in developing countries including Thailand. Vigabatrin, therefore, is the first recommended by Epilepsy Society of Thailand due to ACTH unavailability. Recently, combined steroid treatments (either ACTH or high dose prednisolone) with vigabatrin are superior in cessation of spasms compared to steroid treatment alone. Thus, this study is aimed to compare the efficacy of vigabatrin with high dose prednisolone combination therapy and vigabatrin alone.
Interested in participating?
Request Info2 month–14 month
All sexes
Interventional
Not applicable
Ratchathewi, Bangkok, 10400, Thailand
Location status: Recruiting
Infantile spasms are recognized as epileptic encephalopathy which include the hypsarrhythmia or variants electroencephalographic (EEG) features and psychomotor regression. Various underlying conditions are associated with the infantile spasm included cerebral malformation, hypoxic ischemic encephalopathy, genetic disorders (Down syndrome), tuberous sclerosis complex (TSC), etc. Although vigabatrin has the evidence to use as the first line treatment for infantile spasm related with TSC. Adrenocorticotrophic hormone (ACTH), or high dose prednisolone, or vigabatrin are the first line treatment of IS in non-TSC.
The effectiveness of ACTH versus high dose prednisolone question have not yet definitely answered. Furthermore, ACTH expense and availability are the barriers in developing countries including Thailand. Vigabatrin, therefore, is the first option of therapy recommended by Epilepsy Society of Thailand due to ACTH unavailability. Recently, combined steroid treatments (either ACTH or high dose prednisolone) with vigabatrin are superior in cessation of spasms compared to steroid treatment alone. Questions about the clinical cessation of IS and electrographic remission by combination treatment with vigabatrin and high dose prednisolone compare to vigabatrin alone have not fully elucidated. Thus, this study is aimed to compare the efficacy of vigabatrin with high dose prednisolone combination therapy and vigabatrin alone.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
Other names: Sabril with prednisolone
Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
Other names: Sabril
Time frame: Assessed during Day 14 to Day 42 after treatment.
Defined as no witnessed spasms (either clusters or single spasms) from Day 14 to Day 42 inclusive.
Time frame: Assessed during Day 14 and Day 43 after treatment.
Disappearance of hypsarrhythmia defined by Burden of Amplitudes and Epileptiform Discharges (BASED) scoring system < 2 at Day 14 and Day 43 after treatment.
Time frame: Between Day 14 and Day 21.
the cessation of spasms with the addition of absence of hypsarrhythmia (BASED score < 2) on the Day 14 EEG. Valid Day 14 EEGs will be undertaken between Day 14 and Day 21 inclusive.
Time frame: Between Day 42 and Day 49.
Electroclinical response with the addition of absence of hypsarrhythmia (BASED score < 2) on the Day 42 EEG. Valid Day 42 EEGs will be undertaken between Day 42 and Day 49 inclusive.
Time frame: Day 1 to Day 14
Duration for clinical cessation of spasms after initiation treatment
Time frame: Day 42 to 3 months after treatment
Defined when a cluster of more than one spasm in reported after Day 42. No EEG is required.
Time frame: Day 1 to Day 14, from Day 15 to Day 42, and from Day 43 to 4 months into the trial
Each adverse event will be evaluated by the principal investigator to determine whether in their view it is an adverse reaction. If considered an adverse reaction, it will be reported by using the standard classification.
Time frame: From Day 42 to age 18 months
Epilepsy status and antiepileptic drugs (AEDs) will be recorded by using the following categories: 1) Infantile spasms (clusters of spasms), 2) Any other epileptic seizure including febrile seizures, and 3) Names of any preventive AEDs prescribed
Interested in participating?
Request InfoKullasate Sakpichaisakul
Other Gov
Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04289467
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial DetailsNCT06266234
Brain Diseases, Central Nervous System Diseases
Garches, France
View Trial DetailsNCT07585643
Brain Diseases, Central Nervous System Diseases
Perth, Western Australia, Australia
View Trial DetailsNCT05538936
Brain Diseases, Central Nervous System Diseases
Van, Turkey, Turkey (Türkiye)
View Trial Details